Premium
Regression of human immunodeficiency virus‐associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review
Author(s) -
Franco Juliana Bertoldi,
Maureira Pena Loreto José,
Martins e Martins Fabiana,
Oliveira Marcio Augusto,
Ortega Karem L.
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25446
Subject(s) - medicine , sarcoma , antiretroviral therapy , lesion , kaposi's sarcoma , chemotherapy , human immunodeficiency virus (hiv) , immunopathology , cart , nodule (geology) , sida , radiology , viral disease , pathology , viral load , surgery , immunology , biology , mechanical engineering , paleontology , human herpesvirus , engineering
Background Kaposi's sarcoma (KS) is the most prevalent malignant neoplasia in human immunodeficiency virus positive (HIV+) patients for which the primary mode of management was chemotherapy. Methods We have presented the case of a newly diagnosed HIV+ male patient who was diagnosed with a pedunculated nodule in the anterior region of the hard palate, measuring 3.5 cm in diameter and with 2 months of evolution. Results Histopathological examination confirmed the clinical hypothesis of KS. Soon after the diagnosis, the patient started using combined antiretroviral therapy (Biovir and Kaletra), presenting a significant reduction of the lesion after 4 weeks. With 1.5 cm in diameter, the lesion was surgically removed. The patient was followed‐up for 10 years without any recurrence. Conclusion In antiretroviral‐naive patients with a well‐preserved immune system, the use of cART may be efficient in reducing the progression of the KS lesions, thus avoiding the use of chemotherapeutic agents.